T-Cell Immunotherapies Targeting Histocompatibility and Tumor Antigens in Hematological Malignancies
Over the last decades, T-cell immunotherapy has revealed itself as a powerful, and often curative, strategy to treat blood cancers. In hematopoietic cell transplantation, most of the so-called graft-vs.-leukemia (GVL) effect hinges on the recognition of histocompatibility antigens that reflect immun...
Main Authors: | Valérie Janelle, Caroline Rulleau, Simon Del Testa, Cédric Carli, Jean-Sébastien Delisle |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-02-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2020.00276/full |
Similar Items
-
T-Cell Dysfunction as a Limitation of Adoptive Immunotherapy: Current Concepts and Mitigation Strategies
by: Valérie Janelle, et al.
Published: (2021-02-01) -
Histocompatibility Antigens
by: Mustafa Yilmaz
Published: (2014-02-01) -
T cell recognition of novel shared breast cancer antigens is frequently observed in peripheral blood of breast cancer patients
by: Nadia Viborg, et al.
Published: (2019-12-01) -
Harnessing Dendritic Cells for Tumor Antigen Presentation
by: Stefan Nierkens, et al.
Published: (2011-04-01) -
Chimeric Antigen Receptor-Engineered T Cells in Tumor Immunotherapy: From Bench to Beside
by: Peng WANG
Published: (2017-06-01)